» Articles » PMID: 26765551

Carboxyhemoglobin Levels As a Predictor of Risk for Significant Hyperbilirubinemia in African-American DAT(+) Infants

Overview
Journal J Perinatol
Date 2016 Jan 15
PMID 26765551
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare the degree of hemolysis in a group of direct antiglobulin test (DAT) positive (pos) African-American (AA) infants as measured by carboxyhemoglobin corrected (COHbc) for carbon monoxide in ambient air to a similar group of DAT negative (neg) ABO incompatible infants and a group without blood group incompatibility. To determine if COHbc is a better predictor of significant hyperbilirubinemia than DAT status.

Study Design: A prospective study of 180 AA infants from the Well-Baby Nursery of an inner city community hospital, all of whose mothers were type O pos. Infants (60) were ABO incompatible DAT pos, 60 were ABO incompatible DAT neg and 60 were type O(+). Blood for COHbc was drawn at the time of the infants' initial bilirubin and the infants' precise percentile on the Bhutani nomogram was calculated.

Result: Mean COHbc of type O(+) infants was 0.76±0.21 and 0.78±0.24% for ABO incompatible DAT neg infants (P=0.63). Mean CoHbc for the ABO incompatible DAT pos infants was 1.03±0.41% (P<0.0001 compared with both type O and DAT neg infants). Optimal cutoff on the receiver operating characteristic curve for COHbc to determine the risk for being in the Bhutani curve high risk zone was COHbc >0.90% (area under the curve(AUC) 0.8113). This was similar to the AUC of the receiver operating characteristic curve using any titer strength of DAT pos as a cutoff (0.7960).

Conclusion: Although not greatly superior to the titer strength of DAT pos, COHbc is useful in determining if the etiology of severe hyperbilirubinemia is a hemolytic process.

Citing Articles

End-tidal carbon monoxide for routine monitoring of significant hemolysis in the management of newborn hyperbilirubinemia.

Wells S, Balasubramanian R, Nguyen K, Schutzman D J Perinatol. 2025; .

PMID: 40011553 DOI: 10.1038/s41372-025-02242-z.


Effect of intravenous immunoglobulin on the management of Rh- and ABO-mediated hemolytic disease of the newborn.

Jalali S, Mahdipour S, Asgarzad R, Saadat F Hematol Transfus Cell Ther. 2024; 46 Suppl 5:S57-S64.

PMID: 38719722 PMC: 11670604. DOI: 10.1016/j.htct.2024.03.002.


Effect of genetic variants of bilirubin metabolism on the degree of hyperbilirubinemia in African-American newborns.

Schutzman D, Baudhuin L, Gatien E, Ajayi S, Wong R J Perinatol. 2016; 37(4):432-435.

PMID: 27977017 DOI: 10.1038/jp.2016.232.

References
1.
Beutler E, Gelbart T, Demina A . Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc Natl Acad Sci U S A. 1998; 95(14):8170-4. PMC: 20948. DOI: 10.1073/pnas.95.14.8170. View

2.
Bhutani V, Wong R . Bilirubin-induced neurologic dysfunction (BIND). Semin Fetal Neonatal Med. 2015; 20(1):1. DOI: 10.1016/j.siny.2014.12.010. View

3.
Bhutani V, Johnson L, Sivieri E . Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics. 1999; 103(1):6-14. DOI: 10.1542/peds.103.1.6. View

4.
Slusher T, Zipursky A, Bhutani V . A global need for affordable neonatal jaundice technologies. Semin Perinatol. 2011; 35(3):185-91. DOI: 10.1053/j.semperi.2011.02.014. View

5.
Herschel M, Karrison T, Wen M, Caldarelli L, Baron B . Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates. Pediatrics. 2002; 110(1 Pt 1):127-30. DOI: 10.1542/peds.110.1.127. View